Health · 54 views
Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b…
Summary
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer ( WCLC ). Tarlatamab is a bispecific T-cell engager (BiTE) immunotherapy with established clinical activity in small cell lung cancer and has previously been evaluated using intravenous administration.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- The invisible global health workforce: Why nurses matter more than everContinue reading
- AI measurements of heart scans more strongly linked to patient survival than clinician measurementsContinue reading
- Novel Therapy Lands Speedy Approval for Wart-Like Airway DiseaseContinue reading
- Study Strengthens Case for Stent-Free PCI in De Novo Coronary LesionsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow